A landmark clinical trial published in The Lancet has demonstrated that one year of treatment with abatacept can delay rheumatoid arthritis onset by up to four years in high-risk individuals. This represents a significant breakthrough in autoimmune disease prevention, challenging the long-held assumption that rheumatoid arthritis is inevitable in genetically predisposed populations.
The randomized controlled trial enrolled 213 individuals with arthralgia and specific autoantibodies, identifying them as high-risk candidates. Led by Dr. Danielle Gerlag at Amsterdam University Medical Centers, the study showed that abatacept’s immunosuppressive mechanism—blocking T-cell activation in the autoimmune cascade—provides sustained protective effects even years after treatment discontinuation.
These findings open new therapeutic possibilities for preventing progression to clinically manifest disease in at-risk populations, potentially transforming the treatment paradigm for rheumatoid arthritis.
Read the full article on GMJ Newsroom.
Was this article helpful?
